Karolinska Development's Drug Candidate OG-6219 Update
Karolinska Development AB (Nasdaq Stockholm: KDEV) has recently communicated critical developments regarding the drug candidate OG-6219, which was obtained by Organon in the acquisition of Forendo Pharma. This update comes on the heels of Organon’s announcement concerning the results of a Phase 2 clinical study focused on OG-6219.
Discontinuation of Clinical Development
Following the outcomes from the Phase 2 ELENA proof-of-concept study, it has been determined that OG-6219 did not offer any significant improvement in managing moderate-to-severe pelvic pain associated with endometriosis when compared to a placebo. As a result, Organon has made the decision to halt further clinical development of this candidate.
Background on Acquisition and Future Implications
When Organon acquired Forendo Pharma in 2021, it gained two drug candidate projects, with OG-6219 being the most developed. This transition was significant for Karolinska Development, as part of the acquisition agreement allows it to receive earn-out payments. Prior to Organon's announcement, the company estimated the risk-adjusted net present value (rNPV) of future cash flows, including earn-outs, at around SEK 76.2 million.
Financial Adjustments Ahead
With Organon’s decision to terminate the clinical development of OG-6219, Karolinska Development acknowledges the necessity of implementing an impairment adjustment. This adjustment addresses the potential financial impact due to the discontinuation of the project and is expected to be included in the interim report for the second quarter of 2025.
Management Contact Information
For any inquiries, you can reach out to Viktor Drvota, CEO of Karolinska Development AB, by phone at +46 73 982 52 02 or via email at viktor.drvota@karolinskadevelopment.com. Additionally, Johan Dighed, General Counsel and Deputy CEO, is available at +46 70 207 48 26 or at johan.dighed@karolinskadevelopment.com.
About Karolinska Development AB
Karolinska Development AB specializes in identifying and nurturing groundbreaking medical innovations within Nordic regions. The company is committed to investing in the development and growth of healthcare companies that turn these innovations into products aimed at improving patient outcomes while also providing value for shareholders.
With a strong connection to prestigious institutions like the Karolinska Institutet and other key universities, Karolinska Development seeks to create companies focused on significant medical advancements. The goal is to support scientists and management teams in bringing innovative treatments to market, backed by strategic investment partners.
Company’s Portfolio
Currently, Karolinska Development holds a diverse portfolio that includes eleven companies dedicated to addressing serious and life-threatening medical conditions. The firm prides itself on having a dedicated team of investment professionals who possess extensive experience in building successful companies, ensuring that every project has a substantial chance of success.
Frequently Asked Questions
What is OG-6219?
OG-6219 is a drug candidate that was under development for treating endometriosis-related pain but has now been discontinued by Organon.
Why was the clinical development of OG-6219 discontinued?
The decision to halt the clinical development was based on results from the Phase 2 ELENA study, which did not show significant benefits compared to a placebo.
What are earn-out payments in relation to Karolinska Development?
Earn-out payments are financial settlements that Karolinska Development is entitled to receive as part of its agreement with Organon following the acquisition of Forendo Pharma.
What is the estimated risk-adjusted net present value of future cash flows for Karolinska Development?
Before the announcement of discontinuation, the estimated rNPV for future cash flows was SEK 76.2 million.
How does this affect Karolinska Development financially?
Due to the discontinuation, Karolinska Development will likely make an impairment adjustment affecting its financial statements to reflect the loss of projected earnings from OG-6219.
